Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
C. Kent Osborne(Baylor College of Medicine), Mark Sellers(AstraZeneca (United Kingdom)), Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Carolina Gutiérrez(Baylor College of Medicine), David L. Rimm(Yale University), Patrick Neven(KU Leuven), John R. Mackey(University of Alberta), Patrick Magill(Royal Bournemouth Hospital), Valsamo Anagnostou(Johns Hopkins University), Ilenia Migliaccio(Hospital of Prato), Jean Robert(AstraZeneca (United Kingdom)), Rachel Schiff(Baylor College of Medicine), Craig Underhill(AstraZeneca (United Kingdom))
Cited by 181
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k